Advertisement

Drug Safety

, Volume 21, Issue 2, pp 75–79 | Cite as

Biological Interpretation of Relative Risk

Current Opinion

Abstract

There is widespread interest in assessing the clinical importance of a study result. This goal is impeded, however, by a lack of clarity about the biological interpretability of epidemiological effect measures, such as the relative risk. A relative risk is often interpreted merely as a measure of some vague statistical association, without a view toward a biological effect as an object of measurement. Not infrequently, if it is not statistically significant, the relative risk estimate is ignored completely.

A key to biological interpretation is appreciating the theoretical framework stipulating that outcome rates derived from 2 comparison groups actually represent measures of different effects in the same population. For instance, by using a placebo group to estimate the number of background cases that occurred in the treatment group, an estimate of the number of excess cases that occurred as a result of treatment can be made. This kind of biological entity can be derived from a relative risk, and can be more easily evaluated as to its clinical importance than a statistical association or a statement about statistical significance. Interpretation then becomes a more directed task, with a focus on the validity of certain ancillary hypotheses upon which biological interpretability rests.

Keywords

Relative Risk Adis International Limited Risk Ratio Causal Effect Risk Difference 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rubin DB. Neyman (1923) and causal inference in experiments and observational studies [comment]. Stat Sci 1990; 5: 472–80Google Scholar
  2. 2.
    Lewis D. Causation. J Philos 1973; 70: 566–7CrossRefGoogle Scholar
  3. 3.
    Rothman KJ. Causes. Am J Epidemiol 1976; 104: 587–92PubMedGoogle Scholar
  4. 4.
    Rubin DB. Bayesian inference for causal effects: the role of randomization. Ann Stat 1978; 6: 34–58CrossRefGoogle Scholar
  5. 5.
    Holland PW. Statistics and causal inference. Am Stat Assoc 1986; 81: 945–60CrossRefGoogle Scholar
  6. 6.
    Greenland S, Robins JM. Identifiability, exchangeability, and epidemiologic confounding. Int J Epidemiol 1986; 15: 412–8CrossRefGoogle Scholar
  7. 7.
    Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol 1974; 66: 688–701CrossRefGoogle Scholar
  8. 8.
    Rothman KJ, Greenland S. Mod Epidemiol, Philadelphia: Lippincott-Raven, 1998: 58–62Google Scholar
  9. 9.
    Rubin DB. Practical implication of modes of statistical inference for causal effect and the critical role of the assignment mechanism. Biometrics 1991; 47: 1213–34PubMedCrossRefGoogle Scholar
  10. 10.
    Popper KR. The logic of scientific discovery. New York: Harper & Roe, 1968. [Originally published as Logik der Forschung. Vienna: Springer, 1934]Google Scholar
  11. 11.
    Angell M. The interpretation of epidemiologic studies. N Engl J Med 1990; 323: 823–5PubMedCrossRefGoogle Scholar
  12. 12.
    Morrison DE, Henkel RE, editors. The significance test controversy. Chicago: Aldine Publishing Company, 1970Google Scholar
  13. 13.
    Rothman KJ. A show of confidence. N Engl J Med 1978; 299: 1362–3PubMedCrossRefGoogle Scholar
  14. 14.
    Salsburg DS. The religion of statistics as practiced in medical journals. Am Stat 1985; 39: 220–3Google Scholar
  15. 15.
    Rothman KJ. Significance questing. Ann Int Med 1986; 105: 445–7PubMedGoogle Scholar
  16. 16.
    Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105: 429–35PubMedGoogle Scholar
  17. 17.
    Gardner NJ, Airman DG. Confidence intervals rather than pvalues: estimation rather than hypothesis testing. BMJ 1986; 292: 746–50PubMedCrossRefGoogle Scholar
  18. 18.
    Poole C. Beyond the confidence interval. Am J Pub Health 1987; 77: 195–9CrossRefGoogle Scholar
  19. 19.
    Savitz D. Is statistical significance testing useful in interpreting data? Reprod Toxicol 1993; 7: 95–100PubMedCrossRefGoogle Scholar
  20. 20.
    Cohen J. The earth is round (p<.05). Am Psychol 1994; 47: 997–1003CrossRefGoogle Scholar
  21. 21.
    Borenstein M. The case for confidence intervals in controlled clinical trials. Control Clin Trials 1994; 15: 411–28PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Boehringer Ingelheim Pharmaceuticals, Inc.RidgefieldUSA

Personalised recommendations